CCDC103: A Novel Biomarker with Potential Prognostic in Glioma

Abstract

Abstract The coiled-coil domain-containing protein 103 (CCDC103), a predicted coiled-coil domain containing (CCDC) protein, whose role in tumors has never been reported. However, the diagnostic value and biological function of CCDC103 have not been elucidated in glioma. In this study, immunohistochemistry, qRT-PCR, GrowthCurve and migration experiments were used to explore the roles of CCDC103 on glioma biological function. Differential expression of CCDC103 at the mRNA level was evaluated using the Cancer Genome Atlas (TCGA), GEO and Chinese Glioma Genome Atlas (CGGA) databases. Correlations between CCDC103 expression and clinical outcomes of glioma were explored by TCGA and CGGA databases. GO, KEGG and GSEA were used to explore the molecular function of CCDC103. Different algorithms of immune infiltration were used to analyze the association between CCDC103 and immune infiltration. We found that CCDC103 was highly expressed in glioma tissues and cells, and knockdown of CCDC103 expression can significantly inhibit the growth and migration of glioma cells. In addition, CCDC103 was associated with immune infiltration in glioma and positively correlated with multiple immune checkpoint molecules. In summary, our study indicated that CCDC103 was highly expressed in glioma tissues and cell lines, and that patients with high expression of CCDC103 have a worse prognosis. In addition, knockdown of CCDC103 significantly inhibited the growth and migration of glioma cell lines. These results suggest that CCDC103 plays a crucial funtion in the development of glioma and may act as a new prognostic marker in glioma.